Enliven Therapeutics (ELVN) Competitors $21.85 +0.38 (+1.77%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELVN vs. RARE, RNA, SWTX, ADMA, OGN, BHVN, ALVO, PTCT, ACLX, and RYTMShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), ADMA Biologics (ADMA), Organon & Co. (OGN), Biohaven (BHVN), Alvotech (ALVO), PTC Therapeutics (PTCT), Arcellx (ACLX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Ultragenyx Pharmaceutical Avidity Biosciences SpringWorks Therapeutics ADMA Biologics Organon & Co. Biohaven Alvotech PTC Therapeutics Arcellx Rhythm Pharmaceuticals Enliven Therapeutics (NASDAQ:ELVN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations. Which has more volatility & risk, ELVN or RARE? Enliven Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Is ELVN or RARE more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Enliven Therapeutics' return on equity of -29.46% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.46% -27.33% Ultragenyx Pharmaceutical -101.60%-185.70%-38.25% Does the media prefer ELVN or RARE? In the previous week, Ultragenyx Pharmaceutical had 15 more articles in the media than Enliven Therapeutics. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 0 mentions for Enliven Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.29 beat Enliven Therapeutics' score of 0.25 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Overall Sentiment Enliven Therapeutics Neutral Ultragenyx Pharmaceutical Neutral Do insiders & institutionals have more ownership in ELVN or RARE? 95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ELVN or RARE? Ultragenyx Pharmaceutical received 825 more outperform votes than Enliven Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Enliven Therapeutics an outperform vote while only 77.46% of users gave Ultragenyx Pharmaceutical an outperform vote. CompanyUnderperformOutperformEnliven TherapeuticsOutperform Votes10100.00% Underperform VotesNo VotesUltragenyx PharmaceuticalOutperform Votes83577.46% Underperform Votes24322.54% Which has better valuation & earnings, ELVN or RARE? Enliven Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$71.58M-$1.90-11.50Ultragenyx Pharmaceutical$560.23M7.09-$569.18M-$6.34-6.79 Do analysts prefer ELVN or RARE? Enliven Therapeutics presently has a consensus target price of $38.25, suggesting a potential upside of 75.06%. Ultragenyx Pharmaceutical has a consensus target price of $93.50, suggesting a potential upside of 117.33%. Given Ultragenyx Pharmaceutical's higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Enliven Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 SummaryEnliven Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 18 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$7.07B$5.81B$9.02BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-11.586.0426.2318.96Price / SalesN/A317.07453.4377.29Price / CashN/A67.8344.0437.47Price / Book3.666.777.664.69Net Income-$71.58M$138.11M$3.18B$245.69M7 Day Performance0.78%-1.51%-1.36%-1.85%1 Month Performance-0.68%-1.07%0.73%-1.54%1 Year Performance35.21%-2.80%17.60%14.60% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics1.9749 of 5 stars$21.85+1.8%$38.25+75.1%+29.6%$1.07BN/A-11.5850RAREUltragenyx Pharmaceutical4.6565 of 5 stars$44.78-1.3%$92.43+106.4%-7.1%$4.14B$522.75M-6.921,276Analyst ForecastRNAAvidity Biosciences1.6469 of 5 stars$34.31-1.7%$65.80+91.8%+132.7%$4.09B$9.56M-11.91190SWTXSpringWorks Therapeutics1.2921 of 5 stars$54.00+34.1%$70.00+29.6%+22.8%$4.02B$5.45M-13.92230Earnings ReportAnalyst ForecastInsider TradeNews CoverageHigh Trading VolumeADMAADMA Biologics3.5624 of 5 stars$16.66-0.3%$21.25+27.6%+212.2%$3.94B$258.21M59.50530OGNOrganon & Co.4.8814 of 5 stars$15.04+2.8%$21.33+41.9%-15.2%$3.87B$6.26B2.9810,000BHVNBiohaven3.4053 of 5 stars$38.25-0.5%$63.00+64.7%-15.8%$3.87BN/A-4.09239Short Interest ↓ALVOAlvotech2.4783 of 5 stars$12.75-1.2%$18.00+41.2%-26.7%$3.84B$93.38M-6.891,026News CoveragePTCTPTC Therapeutics3.6605 of 5 stars$49.82+0.7%$57.85+16.1%+93.9%$3.84B$900.66M-8.391,410Analyst ForecastNews CoverageACLXArcellx2.0794 of 5 stars$67.00+0.1%$105.93+58.1%+9.5%$3.62B$110.32M-94.3680Upcoming EarningsRYTMRhythm Pharmaceuticals4.1274 of 5 stars$58.47-1.2%$68.09+16.5%+17.6%$3.59B$77.43M-13.50140Analyst ForecastInsider TradeNews Coverage Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors Avidity Biosciences Competitors SpringWorks Therapeutics Competitors ADMA Biologics Competitors Organon & Co. Competitors Biohaven Competitors Alvotech Competitors PTC Therapeutics Competitors Arcellx Competitors Rhythm Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELVN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELVN Stock Alerts